New drug duo targets Tough-to-Treat breast cancer
NCT ID NCT03090165
Summary
This study is testing whether two existing oral drugs, ribociclib and bicalutamide, work better together to control advanced triple-negative breast cancer that has spread. The trial involves about 37 people whose cancer has a specific marker (the androgen receptor). The main goals are to find a safe dose and see if the combination helps stop the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michigan State University
Lansing, Michigan, 48910, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.